Why the study?
Does rivaroxaban safely prevent stroke and systemic embolism in Korean patients with non-valvular atrial fibrillation in routine clinical practice?
Does rivaroxaban safely prevent stroke and systemic embolism in Korean patients with non-valvular atrial fibrillation in routine clinical practice?
Rivaroxaban demonstrates a favorable safety and efficacy profile for stroke prevention in high-risk Korean patients with non-valvular atrial fibrillation in routine clinical practice.
See the article "A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea" in volume 36 on page 906.
No takes yet. Share an insight, caveat, or question.
Yae Min Park (2021) conducted an editorial in Non-valvular atrial fibrillation (n=844). Rivaroxaban was evaluated on Treatment-emergent major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: